Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

BACKGROUND: A fixed 8-cycle oxaliplatin and capecitabine (XELOX) regimen has been the standard adjuvant therapy for patients with stage III colon cancer. However, completing the full-cycle of oxaliplatin is often associated with severe neurotoxicity. To spare patients from the toxic effects, without...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Commun (Lond)
Главные авторы: Peng, Jianhong, Li, Weihao, Zhang, Rongxin, Lin, Junzhong, Tang, Jinghua, Wen, Yongshan, Lu, Zhenhai, Wu, Xiaojun, Pan, Zhizhong
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796386/
https://ncbi.nlm.nih.gov/pubmed/31619288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0400-x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы